WASHINGTON — Allergan says it will pay $600 million to settle a years-long federal investigation into how it marketed its top-selling drug Botox.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The company says it will plead guilty to one misdeameanor charge of "misbranding," in which the company's marketing led physicians to use Botox for unapproved uses. Those uses included the treatment of headache, pain, spasticity and cerebral palsy.
It says it will pay $375 million in connection with the plea.
In addition, the company will pay $225 million in civil fines related to the investigation, though the company denies liability.
The Department of Justice began investigating Allergan's marketing in 2000. In recent years, federal investigators have reached multi-billion dollar settlements with Pfizer, Eli Lilly and other drug companies over drug marketing practices.
Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.